Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
- PMID: 26211886
- DOI: 10.1016/j.rmed.2015.07.009
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
Keywords: Dual bronchodilators; Exacerbations; LABA/ICS; LABA/LAMA; Lung function.
Comment in
-
Response to Letter to the Editor: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.Respir Med. 2016 Jan;110:81. doi: 10.1016/j.rmed.2015.11.011. Epub 2015 Nov 27. Respir Med. 2016. PMID: 26689766 No abstract available.
Comment on
-
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.Respir Med. 2015 Jul;109(7):870-81. doi: 10.1016/j.rmed.2015.04.018. Epub 2015 May 8. Respir Med. 2015. PMID: 26006754 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
